Skip to main content

Table 6 Six month amputation in NO-CLI Control groups only

From: The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design

 

N

Amp N

Amp %

Jivegard 1995

26

10

38.5%

Lepantalo 1996

136

53

39.0%

Klomp 1999

60

20

33.3%

Amann 2003

39

15

38.5%

Brass 2006

190

16

8.4%

Nikol 2008

56

16

28.6%

Hiatt 2010

259

44

17.0%

Powell 2011

24

6

25.0%

Benoit 2011

14

5

35.7%

 

804

185

23.0%

  1. NO-CLI: No option critical limb ischemia